Drugs / Neo-antigen pulsed Dendritic cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04105582 | Aug 2019 → Dec 2020 | triple-negative breast carcinoma | National University of Colombia | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neo-antigen pulsed Dendritic cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04105582 ↗ |
| Modality | Cell therapy | “Autologous dendritic cells pulsed with tumor-specific neo-antigen (synthetic peptide)” NCT04105582 ↗ |